Report of Foreign Issuer (6-k)

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2017

Commission File Number: 001-36596

___________________

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
( Address of principal executive offices )
___________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[   ]

---

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Trillium Therapeutics Inc.
Date: November 10, 2017
	By:      /s/ James Parsons
	Name: James Parsons
	Title: Chief Financial Officer

2

---

EXHIBIT INDEX

Exhibit	Description
99.1	Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2017 and 2016
99.2	Management's Discussion and Analysis For the Three and Nine Months Ended September 30, 2017 and 2016
99.3	Certificate of Interim Filings - Chief Executive Officer
99.4	Certificate of Interim Filings - Chief Financial Officer
99.5	News Release dated November 10, 2017

---